Overview

HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC

Status:
Recruiting
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with BCLC stage hepatocellular carcinoma (HCC).
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Dongguan People's Hospital
First Affiliated Hospital Xi'an Jiaotong University
First Affiliated Hospital, Sun Yat-Sen University
Guangzhou No.12 People's Hospital
Kaiping Central Hospital
The First Affiliated Hospital of University of South China
Treatments:
Sorafenib